Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Istituto Europeo Di Oncologia S.r.l.
Sponsor

Istituto Europeo Di Oncologia S.r.l.

Italy Via Giuseppe Ripamonti 435, 20141 Milan, Italy

About the sponsor

Research activity includes women at elevated risk of breast cancer, including carriers of pathogenic variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C, and RAD51D, as well as women with risk assessed through established predictive models and those with prior breast intraepithelial neoplasia.

  • Low-dose tamoxifen
  • Lifestyle intervention and dietary modification
  • Breast cancer risk assessment

The clinical focus extends to symptom-linked prevention strategies and hormonal risk modulation in women under surveillance for hereditary or acquired breast cancer risk.

About Specializations

Istituto Europeo Di Oncologia S.r.l. runs clinical trials in conditions such as Intraductal proliferative breast lesion, Breast cancer metastatic, Hormone receptor positive HER2 negative breast cancer, Breast cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

8 clinical trials

Breast cancer metastatic+1

Recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Breast cancer+1

Recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prasterone
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Triple negative breast cancer

Recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Breast neoplasm

Recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Intraductal proliferative breast lesion

Recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iopromide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Breast cancer in situ+1

Not recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tamoxifen Citrate
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Inflammatory carcinoma of the breast

Not recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Neuroendocrine carcinoma

Not recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).